Mechanical circulatory support has emerged as an indispensable treatment for advanced stage heart failure, requiring careful patient selection and timing to optimize outcomes.
Postcardiotomy MCS shows high short-term mortality; single-center data leave open optimal selection and timing for primary support.
Treatment of end-stage heart failure has reached new frontiers. With a scarce availability of hearts, mechanical circulatory support (MCS) has become an integral part of end-stage heart failure treatment and has improved survival. A variety of devices may be instituted either for short or long term support in different clinical indications, such as postcardiotomy circulatory failure, acute cardiogenic shock, chronic heart failure in patients not eligible for a transplant to heart transplant deterioration. Permanent or temporary MCS has emerged as an indispensible treatment for advanced stage heart failure alongside established standard medical procedures. Herein we report brief narrative review of MCS devices used for end-stage heart failure.
No takes yet. Share an insight, caveat, or question.
Svetina et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: